Skinny-label ruling will ‘decimate’ Hatch-Waxman, Fed Circuit told
05-01-2021
JHVEphoto / Shutterstock.com
Teva has urged the US Court of Appeals for the Federal Circuit to rehear its dispute with GlaxoSmithKline (GSK) en banc, claiming that if the decision is upheld, “every skinny-labelled generic is at risk”.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Federal Circuit, Teva, GlaxoSmithKline, GSK, patent infringement, generic, Coreg, induced infringement, skinny labels
